Cargando…

Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity

BACKGROUND: Several radiolabeled prostate-specific membrane antigen (PSMA) inhibitors based on the lysine-urea-glutamate (KuE) motif as the pharmacophore proved to be suitable tools for PET/SPECT imaging of the PSMA expression in prostate cancer patients. PSMA I&T, a theranostic tracer developed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wirtz, Martina, Schmidt, Alexander, Schottelius, Margret, Robu, Stephanie, Günther, Thomas, Schwaiger, Markus, Wester, Hans-Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104465/ https://www.ncbi.nlm.nih.gov/pubmed/30136051 http://dx.doi.org/10.1186/s13550-018-0440-2

Ejemplares similares

Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007
por: Robu, Stephanie, et al.
Publicado: (2018)

Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer
por: Weineisen, Martina, et al.
Publicado: (2014)

Effect of Carbohydration on the Theranostic Tracer PSMA I&T
por: Schmidt, Alexander, et al.
Publicado: (2018)

[(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery
por: Schottelius, Margret, et al.
Publicado: (2015)

First (18)F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo — a comparison to [(68)Ga]pentixafor
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
por: Schottelius, Margret, et al.
Publicado: (2019)

A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency
por: Osl, Theresa, et al.
Publicado: (2020)

The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

[(64)Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model
por: Poschenrieder, Andreas, et al.
Publicado: (2017)

Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE
por: Schottelius, Margret, et al.
Publicado: (2015)

Radiohybrid Ligands: A Novel Tracer Concept Exemplified by (18)F- or (68)Ga-Labeled rhPSMA Inhibitors
por: Wurzer, Alexander, et al.
Publicado: (2020)

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
por: Wang, Hui, et al.
Publicado: (2023)

Automated synthesis of [(18)F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions
por: Wurzer, Alexander, et al.
Publicado: (2021)

Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
por: Felber, Veronika Barbara, et al.
Publicado: (2021)

Validation of [(125)I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in vitro and in vivo
por: Schottelius, Margret, et al.
Publicado: (2019)

[(99cm)Tc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center
por: Werner, P., et al.
Publicado: (2020)

Synthesis and preclinical evaluation of novel (99m)Tc-labeled PSMA ligands for radioguided surgery of prostate cancer
por: Kunert, Jan-Philip, et al.
Publicado: (2023)

Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent
por: Chatalic, Kristell L.S., et al.
Publicado: (2016)

Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging
por: Wester, Hans Jürgen, et al.
Publicado: (2015)

[(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent
por: Schottelius, Margret, et al.
Publicado: (2017)

In Vivo Targeting of CXCR4—New Horizons
por: Schottelius, Margret, et al.
Publicado: (2021)

GCP III is not the “off-target” for urea-based PSMA ligands
por: Lee, Zhenghong, et al.
Publicado: (2023)

Synthesis of lipophilic 1-deoxygalactonojirimycin derivatives as D-galactosidase inhibitors
por: Schitter, Georg, et al.
Publicado: (2010)

Synthesis and Preclinical Evaluation of (177)Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer
por: Wurzer, Alexander, et al.
Publicado: (2022)

Synthesis, (123)I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures
por: Hasnowo, Lutfi A., et al.
Publicado: (2023)

Synthesis of an Al(18)F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform
por: Giglio, Javier, et al.
Publicado: (2018)

Preclinical biodistribution and dosimetry and human biodistribution comparing (18)F-rhPSMA-7 and single isomer (18)F-rhPSMA-7.3
por: Knorr, Karina, et al.
Publicado: (2022)

Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitors
por: Rogers, O. C., et al.
Publicado: (2021)

CXCR4-directed theranostics in oncology and inflammation
por: Kircher, Malte, et al.
Publicado: (2018)

Preclinical comparison of four [(18)F, (nat)Ga]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics
por: Wurzer, Alexander, et al.
Publicado: (2020)

Design, Synthesis, Computational, and Preclinical Evaluation of (nat)Ti/(45)Ti-Labeled Urea-Based Glutamate PSMA Ligand
por: Søborg Pedersen, Kristina, et al.
Publicado: (2020)

[(99m)Tc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experience
por: Konrad, Matthias, et al.
Publicado: (2023)

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma
por: Philipp-Abbrederis, Kathrin, et al.
Publicado: (2015)

Glu-Urea-Lys Scaffold Functionalized Superparamagnetic Iron Oxide Nanoparticles Targeting PSMA for In Vivo Molecular MRI of Prostate Cancer
por: Zhou, Wei, et al.
Publicado: (2022)

Hydrotropic Solubilization of Lipophilic Drugs for Oral Delivery: The Effects of Urea and Nicotinamide on Carbamazepine Solubility–Permeability Interplay
por: Beig, Avital, et al.
Publicado: (2016)

Urea-based amino sugar agent clears murine liver and preserves protein fluorescence and lipophilic dyes
por: Hough, Michelle, et al.
Publicado: (2021)

Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study
por: Dewes, Sabrina, et al.
Publicado: (2016)

PET Imaging of Integrin αVβ3 Expression
por: Beer, Ambros J., et al.
Publicado: (2011)

Radiolabeled PSMA Inhibitors
por: Neels, Oliver C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uk8v887pc7gokdorbln97sqtr9